Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 10,660,000 shares, a drop of 19.4% from the September 15th total of 13,220,000 shares. Currently, 9.4% of the company’s shares are sold short. Based on an average daily trading volume, of 667,100 shares, the short-interest ratio is presently 16.0 days.
Lyell Immunopharma Stock Performance
LYEL opened at $1.18 on Monday. The business’s 50-day simple moving average is $1.35 and its 200 day simple moving average is $1.88. Lyell Immunopharma has a 52-week low of $1.06 and a 52-week high of $3.26. The firm has a market capitalization of $300.83 million, a PE ratio of -1.31 and a beta of -0.53.
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. The company had revenue of $0.01 million for the quarter. On average, research analysts forecast that Lyell Immunopharma will post -0.85 earnings per share for the current year.
Analyst Upgrades and Downgrades
Read Our Latest Report on Lyell Immunopharma
Institutional Trading of Lyell Immunopharma
Large investors have recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Lyell Immunopharma in the first quarter valued at approximately $191,000. Acadian Asset Management LLC acquired a new stake in Lyell Immunopharma during the 1st quarter valued at $173,000. TD Asset Management Inc boosted its position in Lyell Immunopharma by 4.2% during the second quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock worth $1,457,000 after purchasing an additional 40,800 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Lyell Immunopharma during the first quarter worth $64,000. Finally, Bank of New York Mellon Corp boosted its position in Lyell Immunopharma by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock worth $974,000 after purchasing an additional 38,487 shares during the period. Institutional investors and hedge funds own 66.05% of the company’s stock.
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Further Reading
- Five stocks we like better than Lyell Immunopharma
- Quiet Period Expirations Explained
- JPMorgan Can Hit New Highs This Year: Here’s Why
- How to Start Investing in Real Estate
- Best Pharma Stocks for Long-Term Investors: Growth and Dividends
- How to Use the MarketBeat Dividend Calculator
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.